Original StudiesConcentrations of protease inhibitors in cord blood after in utero exposureMIROCHNICK, MARK MD; DORENBAUM, ALEX MD; HOLLAND, DIANE MPHIL; CUNNINGHAM-SCHRADER, BETHANN MS; CUNNINGHAM, COLLEEN MD; GELBER, RICHARD PHD; MOFENSON, LYNNE MD; CULNANE, MARY MS; CONNOR, JAMES MD; SULLIVAN, JOHN L. MDAuthor Information From Boston University School of Medicine (MM) and Statistical and Data Analysis Center/Harvard School of Public Health (RG), Boston, MA; Chiron Corp., Emeryville, CA (AD); University of California San Diego, San Diego, CA (DH, JC); Frontier Science and Technology Research Foundation, Amherst, NY (BCS); State University of New York, Upstate Medical University, Syracuse, NY (CC); National Institute of Child Health and Human Development (LM) and National Institute of Allergy and Infections Diseases (MC), National Institutes of Health, Bethesda, MD; and University of Massachusetts Medical School, Worcester, MA (JLS). Accepted for publication April 23, 2002. Presented in part at the Eighth Conference on Retroviruses and Opportunistic Infections. Reprints not available. The Pediatric Infectious Disease Journal: September 2002 - Volume 21 - Issue 9 - p 835-838 Buy Abstract Objective. To determine the concentrations of protease inhibitors in cord blood after prenatal protease inhibitor use by pregnant women. Design. Retrospective analysis of samples collected in a clinical trial. Methods. Protease inhibitor concentrations were measured in cord blood samples collected from women enrolling in the PACTG 316 study who were receiving prenatal protease inhibitor antiretroviral therapy. Results. In cord blood samples from 68 women treated with protease inhibitors during pregnancy, the concentration of these drugs was below the assay lower limit of detection in most samples, including all samples from women receiving indinavir (n = 21) and saquinavir (n = 8), 5 of 6 samples (83%) from women receiving ritonavir and 24 of 38 samples (63%) from women receiving nelfinavir. Conclusions. Low protease inhibitor concentrations in the fetus decrease the likelihood of teratogenic and toxic effects of these drugs but could fail to provide protection from transplacental or intrapartum transmission of HIV-1. © 2002 Lippincott Williams & Wilkins, Inc.